Why Oral Insulin Remains a Challenge: Barriers to Pill Formulation

Insulin is a peptide hormone that cannot be delivered effectively as a pill due to multiple physiological barriers. Despite decades of research, injectable insulin (pens, pumps) remains the standard.

Major Barriers

  1. Enzymatic degradation: Gastric pepsin, pancreatic proteases (trypsin, chymotrypsin) rapidly hydrolyze insulin into inactive fragments.
  2. Poor intestinal absorption: Insulin's large size (~5.8 kDa), hydrophilicity, and lack of specific transporters limit paracellular/transcellular uptake (<1% bioavailability).
  3. First-pass hepatic metabolism: Absorbed insulin enters portal circulation → liver extracts 50–80% before reaching systemic circulation.
  4. Instability: Sensitive to pH, temperature, agitation, and oxidation. Formulation must protect integrity through GI tract.
  5. Dosing precision: Insulin requires precise, individualized dosing; oral delivery variability risks hypoglycemia/hyperglycemia.

Current Research Strategies

  • Enteric coatings, enzyme inhibitors (e.g., sodium caprate), nanoparticle encapsulation, mucoadhesive polymers, permeation enhancers.
  • Oral insulin candidates in clinical trials (e.g., ORMD-0801, HDV-I) show modest bioavailability (~5–15%) but not yet approved for routine use.
  • Alternative non-injectable routes: inhaled (Afrezza®), buccal, nasal, transdermal—each with own challenges.

Until bioavailability, consistency, and cost-effectiveness match injections, oral insulin remains experimental.

Diabetes - Related Articles